← Eichor
Study identifier: NCT06995261 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Follitropin Delta in Long GnRH-agonist Protocol

Condition: Infertility (IVF Patients) · Infertility · Infertility Drugs  ·  Sponsor: Prof. Dr. med. M.Sc. Georg Griesinger

PhaseN/A
Planned participants350
Who can joinFemale, 18 Years to 44 Years
Healthy volunteersNo

About this study

The REWAG study ("Real-world Evaluation of Women undergoing Agonist protocol with Follitropin delta") is a non-interventional observational study conducted across several fertility centers in Germany. The goal of this study is to evaluate how well a personalized dosing regimen of a hormone called Follitropin delta works in women undergoing controlled ovarian stimulation (COS) for in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) using a long GnRH agonist protocol. Follitropin delta is a recombinant follicle-stimulating hormone (rFSH) that allows for individualized dosing based on a woman's weight and a blood marker called anti-Müllerian hormone (AMH). This personalized approach may help to better balance the stimulation of the ovaries, aiming to reduce the risk of overstimulation (OHSS) while still achieving good treatment outcomes. The study will include approximately 350 women who are undergoing routine IVF/ICSI treatment. No experimental drugs or procedures are involved. All treatment decisions remain the responsibility of the attending physicians and follow standard clinical practice. Data will be collected only from routine visits and medical documentation, with no additional interventions required for participation. Researchers will analyze outcomes such as the number of eggs retrieved, pregnancy rates, treatment cancellations, and any side effects. The study will also look at whether certain patient characteristics can predict how well the trea…

This description comes directly from the study's public registry record.

Talk to the study team

Georg Griesinger, MD  ·  +49 451 505 778 212  ·  georg.griesinger@uni-luebeck.de

Lilit Kamalyan, MD, PhD  ·  +49 451 505 778 212  ·  Lilit.Kamalyan@uksh.de

Always discuss trial participation with your own doctor first.

Locations (4)

Department of Obstetrics, Gynecology and Reproductive Endocrinology (UniKiD), Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University DüsseldorfDüsseldorf, North Rhine-Westphalia, GermanyRecruiting
Center for Reproductive Medicine, IVF SAARSaarbrücken, Saarland, GermanyRecruiting
Department of Reproductive Medicine and Gynecological Endocrinology, University Hospital of Schleswig-Holstein, Campus KielKiel, Schleswig-Holstein, GermanyRecruiting
Department of Reproductive Medicine and Gynecological Endocrinology, University Hospital of Schleswig-Holstein, Campus LübeckLübeck, Schleswig-Holstein, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06995261